Comprehensive Monograph on Brivaracetam

I. Executive Summary

Brivaracetam, marketed as Briviact®, is a third-generation antiepileptic drug (AED) developed as a chemical analog of levetiracetam.[1] Its primary mechanism of action is characterized by a high-affinity, selective binding to the synaptic vesicle glycoprotein 2A (SV2A), a key protein in the modulation of neurotransmitter release.[3] This interaction is significantly more potent than that of its predecessor, with a 15- to 30-fold greater affinity for the SV2A target, which is believed to underpin its potent anticonvulsant effects.[4]

Clinically, brivaracetam is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of partial-onset seizures, with indications spanning from monotherapy to adjunctive treatment in both adult and pediatric populations as young as one month of age.[7] Its efficacy has been robustly demonstrated in several pivotal Phase III clinical trials, where it significantly reduced seizure frequency compared to placebo.[10] A key clinical advantage is its favorable pharmacokinetic profile, which includes rapid and near-complete oral absorption, high bioavailability approaching 100%, low plasma protein binding, and rapid penetration into the central nervous system.[1] This profile allows for the initiation of treatment at a therapeutic dose without the need for gradual titration, facilitating a rapid onset of clinical effect.[4]

The safety profile of brivaracetam is generally well-tolerated, with the most common adverse effects being central nervous system-related, such as somnolence, dizziness, and fatigue.[1] While it carries the standard class warnings for AEDs, including the risk of suicidal ideation and psychiatric adverse reactions, clinical and post-marketing data suggest a potentially lower incidence of behavioral and psychiatric side effects compared to levetiracetam, making it a valuable alternative for patients who experience such intolerances.[15] Brivaracetam is classified as a Schedule V controlled substance in the U.S. due to a low potential for abuse.[17] This monograph provides a comprehensive review of its pharmacology, clinical efficacy, safety, and therapeutic role in the management of epilepsy.

II. Introduction and Drug Profile

A. Overview and Therapeutic Class

Brivaracetam is a third-generation antiepileptic drug belonging to the pyrrolidine anticonvulsant and racetam derivative classes.[5] Developed by UCB Pharma, it is a 4-n-propyl analogue of levetiracetam, which was rationally designed through a targeted drug discovery program aimed at identifying molecules with enhanced binding affinity and selectivity for the synaptic vesicle protein 2A (SV2A).[1] This targeted development sought to build upon the established efficacy of levetiracetam while potentially improving the tolerability profile. Brivaracetam is classified as a selective, high-affinity ligand for SV2A and is categorized among miscellaneous anticonvulsants.[5]

B. Regulatory History and Approval Milestones

Brivaracetam, under the trade name Briviact®, received its initial marketing authorizations in early 2016, with approval from the European Medicines Agency (EMA) in January and the U.S. Food and Drug Administration (FDA) on February 19, 2016.[8] The initial indication was for adjunctive therapy in the treatment of partial-onset seizures (POS) in patients aged 16 years and older.[2]

The clinical utility and robust safety data of brivaracetam led to a notably rapid expansion of its approved indications. This swift regulatory progression reflects a high degree of confidence in the drug's clinical profile. In September 2017, just over a year and a half after its initial approval, the FDA expanded its label to include monotherapy for adults with POS.[8] This monotherapy approval was granted via a newly established regulatory pathway that allows for the extrapolation of efficacy and safety from adjunctive therapy trials, enabling new treatment options to reach patients more quickly.[13]

Subsequent approvals further broadened its use in younger populations. In May 2018, the FDA extended the indication to include adjunctive therapy for children aged four years and older, and in August 2021, this was further expanded to include patients as young as one month of age for both monotherapy and adjunctive treatment.[8] The EMA has authorized its use as an add-on therapy for patients from two years of age.[9]

C. Chemical and Physical Properties

Brivaracetam is a small molecule drug with well-defined chemical and physical characteristics.

Chemical Identity

• IUPAC Name: (2S)−2−butanamide.[1]
• Synonyms: Briviact, UCB 34714, (αS,4R)−α−Ethyl−2−oxo−4−propyl−1−pyrrolidineacetamide.[24]
• Chemical Formula: C11​H20​N2​O2​.[1]
• Molar Mass: 212.29 g·mol⁻¹.[1]

Regulatory Identifiers

• DrugBank ID: DB05541.[1]
• CAS Number: 357336-20-0.[1]
• UNII: U863JGG2IA.[1]
• DEA Code Number: 2710 (Schedule V).[17]

Physical Characteristics

• Appearance: A white to off-white crystalline solid.[27]
• Melting Point: The melting point ranges from 72 to 77 °C [1], with a more precise measurement reported at 76.38 °C.[25]
• Solubility: Brivaracetam is highly soluble in aqueous solutions, including water (up to 100 mM) and phosphate-buffered saline (PBS) at pH 7.2. It is also highly soluble in organic solvents such as dimethyl sulfoxide (DMSO), ethanol, and methanol.[24]
• Stability: The compound is stable for at least five years when stored under recommended conditions at -20 °C.[27]
• Specific Rotation: [α]D​ −60°.[1]

III. Clinical Pharmacology

A. Pharmacodynamics and Mechanism of Action

The development of brivaracetam was a direct result of a rational drug design program intended to improve upon the properties of levetiracetam. This targeted approach is central to understanding its distinct pharmacological profile. The program's goal was to identify a molecule with greater binding affinity and selectivity for SV2A, which was achieved with brivaracetam.[4] This enhanced affinity is hypothesized to be the foundation for its potent anticonvulsant activity and its differentiated clinical profile, particularly regarding its tolerability.

Primary Mechanism: High-Affinity, Selective Binding to SV2A

The principal mechanism of action of brivaracetam is its high and selective binding to the synaptic vesicle glycoprotein 2A (SV2A).[1] SV2A is a ubiquitous transmembrane protein found on presynaptic vesicles throughout the central nervous system and is critically involved in the regulation of synaptic vesicle exocytosis and neurotransmitter release.[2] While the precise downstream effects of SV2A binding are not fully elucidated, it is believed that by binding to SV2A, brivaracetam modulates this process. This modulation is thought to stabilize neuronal activity by reducing the release of excitatory neurotransmitters, particularly during the trains of high-frequency neuronal firing that characterize epileptic seizures.[1] Studies in animals deficient in SV2A have shown an increased propensity for seizures, underscoring the protein's role in maintaining normal neuronal excitability.[2] The in vitro binding affinity (

Kd​) of brivaracetam for human SV2A is approximately 50 nM.[24]

Secondary and Ancillary Mechanisms

While SV2A binding is the primary mechanism, some studies have suggested that brivaracetam may possess weak inhibitory activity on voltage-gated sodium channels.[12] This action could theoretically contribute to its overall antiepileptic effect by further stabilizing neuronal membranes against hyperexcitability. However, this is considered a secondary and much less significant mechanism compared to its potent SV2A activity. Importantly, and in contrast to levetiracetam, brivaracetam does not appear to interact with other common AED targets, such as AMPA receptors or high-voltage-gated calcium channels, at therapeutically relevant concentrations.[4]

Comparative Analysis of SV2A Interaction: Brivaracetam vs. Levetiracetam

A key distinction of brivaracetam is its superior interaction with the SV2A target compared to levetiracetam. Brivaracetam demonstrates a 15- to 30-fold higher binding affinity for SV2A.[1] This higher potency is complemented by greater selectivity. Furthermore, evidence from radioligand binding studies suggests that the two drugs may not interact with SV2A identically; they may bind to different sites on the protein or interact with different conformational states of the protein.[4] This differential interaction could account for some of the observed pharmacological differences between the two drugs beyond simple potency.

Another critical distinction is rooted in their physicochemical properties. Brivaracetam is more lipophilic than levetiracetam, a characteristic that facilitates faster and more efficient penetration of the blood-brain barrier (BBB).[3] Following intravenous administration, brivaracetam achieves peak concentrations in the brain and engages with the SV2A target within minutes, compared to the up to an hour required for levetiracetam.[33] This rapid central nervous system entry suggests a faster onset of action, which is a significant clinical advantage.

B. Pharmacokinetics and Metabolism (ADME Profile)

Brivaracetam possesses a highly favorable and predictable pharmacokinetic profile, which underpins many of its clinical advantages, including ease of use and reliability. Its ADME (Absorption, Distribution, Metabolism, and Excretion) characteristics are well-defined and contribute to its straightforward dosing regimens.

Absorption

Brivaracetam is rapidly and almost completely absorbed following oral administration, with an absolute bioavailability approaching 100%.[1] Its pharmacokinetics are linear and dose-proportional across a wide therapeutic range (10 to 600 mg), meaning that changes in dose result in proportional changes in plasma concentration.[1] When administered as a tablet without food, the median time to reach maximum plasma concentration (

Tmax​) is approximately 1 hour.[3] Co-administration with a high-fat meal can slow the rate of absorption, delaying

Tmax​ by about 3 hours, but it does not meaningfully affect the overall extent of absorption (AUC), which remains unchanged.[3] This allows the drug to be taken with or without food without compromising efficacy.

Distribution

The drug is widely distributed throughout the body, with a volume of distribution of approximately 0.5 L/kg, which is similar to that of total body water.[3] A key feature of brivaracetam is its low binding to plasma proteins (≤20%).[1] This low level of protein binding minimizes the potential for displacement-based drug-drug interactions, a common concern with many other AEDs, particularly in patients on polypharmacy. Its high lipophilicity allows it to rapidly cross the blood-brain barrier via passive diffusion, without reliance on active transporters.[3]

Metabolism

Brivaracetam is extensively metabolized, with over 90% of the administered dose being cleared via metabolic pathways.[1] Less than 10% of the parent drug is excreted unchanged in the urine.[3] The metabolism proceeds via two main pathways:

1. Primary Pathway: The predominant metabolic route is the hydrolysis of the amide moiety, a reaction mediated by both hepatic and extra-hepatic amidase enzymes. This process forms a pharmacologically inactive carboxylic acid metabolite.[1] The reliance on a non-CYP450 enzyme system for its primary clearance is a significant advantage, as it reduces the potential for many common drug-drug interactions.
2. Secondary Pathway: A secondary, minor pathway involves the hydroxylation of the propyl side chain. This reaction is primarily mediated by the cytochrome P450 enzyme CYP2C19.[1] Other CYP enzymes, including CYP2C8, CYP3A4, and CYP2B6, play a minimal role.[12]

All three major metabolites—the hydroxy, acid, and hydroxyacid derivatives—are pharmacologically inactive, meaning they do not contribute to the drug's therapeutic effect or its side-effect profile.[1]

Excretion

Elimination of brivaracetam and its metabolites is primarily through the kidneys. More than 95% of an administered dose is recovered in the urine within 72 hours.[1] In contrast, fecal excretion is negligible, accounting for less than 1% of the dose.[3] The terminal plasma elimination half-life (

t1/2​) is consistently reported to be approximately 9 hours, which supports a convenient twice-daily dosing schedule.[1]

Pharmacogenetics: The Role of CYP2C19 Polymorphisms

While the secondary metabolic pathway via CYP2C19 is minor, it has clinically relevant implications. Genetic variations in the CYP2C19 gene can lead to reduced or absent enzyme activity. Individuals with these variations, known as "CYP2C19 poor metabolizers," are less able to hydroxylate brivaracetam.[1] This impaired metabolism leads to an increase in the systemic exposure to the parent drug by 22% to 42%.[1] This elevated exposure may, in turn, increase the risk of dose-related adverse effects, such as somnolence and dizziness. Consequently, the FDA-approved prescribing information advises that a dose reduction may be necessary for patients known to be CYP2C19 poor metabolizers or for those taking strong inhibitors of the CYP2C19 enzyme.[1] This highlights a specific pharmacogenetic consideration that, while not affecting the majority of patients, is an important nuance for personalized medicine.

Table 1: Key Pharmacokinetic Parameters of Brivaracetam

Parameter	Value	Clinical Implication	Source(s)
Bioavailability (Oral)	Nearly 100%	Oral and intravenous doses are effectively interchangeable. Predictable plasma levels.	1
Time to Peak Plasma Conc. (Tmax​)	~1 hour (fasted); ~4 hours (fed)	Rapid onset of action. Food delays but does not reduce absorption.	3
Plasma Protein Binding	≤20%	Low potential for displacement interactions with other highly protein-bound drugs.	1
Volume of Distribution (Vd​)	~0.5 L/kg	Wide distribution into tissues, including rapid entry into the central nervous system.	3
Primary Metabolism	Hydrolysis via amidase	Primary clearance pathway is not dependent on the CYP450 system, reducing interaction risk.	1
Secondary Metabolism	Hydroxylation via CYP2C19	Creates potential for interactions with CYP2C19 inducers/inhibitors and relevance for poor metabolizers.	1
Key Metabolites	Hydroxy, acid, hydroxyacid	All major metabolites are pharmacologically inactive, avoiding concerns of active metabolite accumulation.	1
Elimination Half-Life (t1/2​)	~9 hours	Supports a convenient twice-daily (BID) dosing regimen.	1
Route of Excretion	Renal (>95%)	Primarily cleared by the kidneys as metabolites. Parent drug clearance is mainly metabolic.	1
% Excreted Unchanged	<10%	Extensive metabolism means dose adjustments for renal impairment are not typically needed for the parent drug.	3

IV. Clinical Efficacy in Partial-Onset Seizures

A. Review of Pivotal Phase III Adjunctive Therapy Trials

The clinical efficacy of brivaracetam as an adjunctive therapy for partial-onset seizures (POS) was firmly established in three large, pivotal, multicenter, randomized, double-blind, placebo-controlled Phase III studies: NCT00490035, NCT00464269, and NCT01261325.[10] These trials enrolled adult patients (aged 16–80 years) whose seizures were inadequately controlled by one or two concomitant AEDs.

A pooled analysis of these three studies, comprising an efficacy population of 1,160 patients, provides the most robust evidence for its effectiveness.[10] Patients were randomized to receive fixed doses of brivaracetam (50, 100, or 200 mg/day) or placebo for a 12-week treatment period, following an 8-week baseline period. Notably, patients receiving concomitant levetiracetam were excluded from this primary efficacy analysis, a design choice reflecting the shared mechanism of action and the clinical question of brivaracetam's efficacy as an alternative, not an addition, to levetiracetam.

The results demonstrated a statistically significant and clinically meaningful reduction in seizure frequency across all tested doses. A detailed analysis of the dose-response relationship from these trials reveals a notable pattern. While efficacy clearly increases from the 50 mg/day dose to the 100 mg/day dose, it appears to reach a plateau at higher doses. For instance, the 50% responder rate improves from 34.2% at 50 mg/day to 39.5% at 100 mg/day, but then slightly decreases to 37.8% at the 200 mg/day dose.[10] A similar trend is observed in the percent reduction in seizure frequency over placebo. This suggests that for many patients, the 100 mg/day dose may represent an optimal balance of efficacy and tolerability, with limited additional seizure control offered at the maximum 200 mg/day dose. The key efficacy outcomes from the pooled analysis are summarized in Table 2.

Table 2: Summary of Pivotal Phase III Clinical Trial Efficacy Outcomes (Pooled Data)

Efficacy Endpoint	Placebo (N=418)	Brivaracetam 50 mg/day (N=161)	Brivaracetam 100 mg/day (N=332)	Brivaracetam 200 mg/day (N=249)
Median % Reduction in POS Frequency from Baseline	17.2%	34.7%	37.6%	35.6%
% Reduction in POS Frequency over Placebo (95% CI)	N/A	19.5% (8.0%–29.6%)	24.4% (16.8%–31.2%)	24.0% (15.3%–31.8%)
≥50% Responder Rate (%)	20.3%	34.2% (p=0.0015)	39.5% (p<0.00001)	37.8% (p=0.00003)
Seizure Freedom Rate (%)	0.5%	2.5%	5.1%	4.0%
Data sourced from the pooled analysis of studies NCT00490035, NCT00464269, and NCT01261325.10 P-values represent comparison to placebo.

The efficacy of brivaracetam was further confirmed in a dedicated Phase III trial conducted in an adult Asian population (NCT03083665), which showed consistent and significant seizure reduction, demonstrating its effectiveness across different ethnic backgrounds.[40]

B. Analysis of Monotherapy Efficacy Data

The FDA approved brivaracetam for use as monotherapy in September 2017, a significant expansion of its initial adjunctive indication.[8] This approval was notably based on an extrapolation of the extensive and robust data from the adjunctive therapy trials, a modern regulatory approach supported by an FDA General Advice Letter.[13] This pathway allows for faster approval of monotherapy indications for AEDs with well-established adjunctive efficacy, thereby accelerating patient access. While a dedicated conversion-to-monotherapy study (NCT00698581) was initiated, it was terminated early after an interim analysis suggested it was unlikely to meet its primary efficacy endpoint, though no new safety concerns were raised.[41] Despite this, real-world evidence has since supported its use as both a first-line monotherapy and in conversion-to-monotherapy settings, with one study reporting 12-month seizure-freedom rates as high as 75% in first-line use.[42]

C. Long-Term Extension Studies

The durability of brivaracetam's efficacy and its long-term safety profile have been assessed in several open-label extension studies, where patients who completed the pivotal trials could continue treatment (e.g., NCT00150800, NCT01339559).[38] Data from these long-term follow-up studies have shown that the initial therapeutic response is well-maintained over extended periods, with some patients followed for up to 14 years.[5] These studies also demonstrated high retention rates and a consistent safety profile, confirming its suitability for chronic management of epilepsy.[5]

D. Efficacy in Pediatric Populations

The approval of brivaracetam for pediatric patients down to one month of age was primarily based on pharmacokinetic bridging studies rather than large-scale efficacy trials.[9] These studies, such as NCT00422422 and NCT01364597, established weight-based dosing regimens that achieve plasma concentrations in children comparable to the effective concentrations observed in adults.[22] This approach allows for the extrapolation of efficacy from the adult population to pediatric patients, a common and accepted regulatory strategy for AEDs. The open-label trial data confirmed that brivaracetam was well-tolerated in children from one month to 16 years of age.[22]

V. Safety and Tolerability Profile

A. Common and Significant Adverse Drug Reactions (ADRs)

The safety profile of brivaracetam has been characterized in a large clinical development program involving over 3,000 patients.[19] The most frequently reported adverse drug reactions are predominantly related to the central nervous system, consistent with its mechanism of action. These effects are generally reported as mild to moderate in severity and are most prominent upon treatment initiation, often diminishing with continued use.[31]

In pooled analyses of placebo-controlled trials, the most common ADRs (occurring in at least 5% of patients and at least 2% more frequently than placebo) were [1]:

• Somnolence and sedation: Reported in 15.2% of brivaracetam-treated patients versus 8.5% of those on placebo.
• Dizziness: Reported in 11.2% versus 7.2% for placebo.
• Fatigue: Reported in 8.7% versus 3.7% for placebo.
• Nausea and vomiting: Reported in approximately 5% of patients.[46]

Other less frequent but notable adverse effects include irritability, insomnia, depression, anxiety, asthenia, ataxia, and nystagmus.[47] The overall safety profile in pediatric patients is similar to that observed in adults.[7]

B. Warnings and Precautions

The FDA-approved prescribing information for brivaracetam includes several important warnings and precautions that clinicians must consider.

Suicidal Behavior and Ideation

Consistent with the class warning for all antiepileptic drugs, brivaracetam carries an increased risk of suicidal thoughts and behavior. Clinical studies have shown this risk to be approximately 1 in 500 patients.[7] It is imperative that patients, their families, and caregivers are counseled to monitor for the emergence or worsening of depression, unusual changes in mood or behavior, and any suicidal ideation or self-harming behavior, and to report such symptoms to a healthcare provider immediately.[35]

Neurological Adverse Reactions

The most common tolerability issues are neurological. Somnolence, fatigue, dizziness, and disturbances in balance and coordination are frequently reported and can be severe.[35] These effects are often dose-dependent and most pronounced early in treatment. Patients must be cautioned against driving, operating heavy machinery, or engaging in other hazardous activities until they have gained sufficient experience to gauge how the medication affects their alertness and coordination.[53]

Psychiatric Adverse Reactions

Brivaracetam can cause a range of psychiatric adverse reactions, including both non-psychotic and psychotic symptoms. In clinical trials, such events were reported in approximately 13% of patients treated with brivaracetam compared to 8% of patients on placebo.[45] These reactions can include irritability, anxiety, depression, aggression, agitation, mood swings, and hostility.[7] While often chosen for its potentially more favorable psychiatric profile compared to levetiracetam, it is crucial to recognize that brivaracetam is not free from this risk. It represents a relative improvement, not an elimination of risk. Rare cases of psychotic symptoms, such as hallucinations and delusions, have also been reported.[52] Patients with a history of depression or mental illness should be treated with caution, and all patients should be monitored for these symptoms.[54]

Hypersensitivity Reactions

Although rare, serious hypersensitivity reactions, including bronchospasm and angioedema, have been associated with brivaracetam use.[35] The medication is contraindicated in patients with a known prior hypersensitivity reaction to brivaracetam or any of its inactive ingredients.[35] Patients should be advised to seek immediate medical attention if they experience symptoms such as difficulty breathing, wheezing, or swelling of the face, lips, or throat.

Withdrawal of Antiepileptic Drugs

As with all AEDs, abrupt discontinuation of brivaracetam should be avoided. To minimize the risk of increased seizure frequency and the potential for precipitating status epilepticus, the drug should be withdrawn gradually.[7]

C. Controlled Substance Classification

In the United States, brivaracetam is regulated as a Schedule V controlled substance by the Drug Enforcement Administration (DEA).[17] This classification indicates a low potential for abuse relative to substances in Schedule IV. The scheduling was based on reports of euphoric mood in some individuals at high therapeutic doses, suggesting a potential for psychological dependence.[27] Clinicians should be mindful of this, particularly in patients with a history of substance abuse.[7]

VI. Dosage, Administration, and Drug Interactions

A. Dosing and Administration Guidelines

Brivaracetam offers flexible administration with multiple formulations and a straightforward dosing strategy that does not require initial titration.

Formulations

Brivaracetam is available in three formulations to accommodate different patient needs [7]:

• Film-coated Tablets: Available in strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg.[35]
• Oral Solution: A raspberry-flavored liquid with a concentration of 10 mg/mL, suitable for pediatric patients or those with difficulty swallowing tablets.[35]
• Intravenous (IV) Injection: A solution containing 50 mg/5 mL in a single-dose vial, intended for temporary use when oral administration is not feasible.[35]

Administration

The medication is administered twice daily and can be taken with or without food, as food does not clinically impact its overall absorption.[57] Tablets should be swallowed whole and not crushed or chewed.[57] The IV formulation can be administered as a bolus injection or as an infusion over 2 to 15 minutes.[35] Due to its near-100% bioavailability, oral and IV doses are equivalent and can be used interchangeably, facilitating seamless transitions in care settings.[59]

Recommended Dosing

A significant clinical advantage of brivaracetam is that treatment can be initiated at a therapeutic dose without a gradual escalation period.[4] Dosing is adjusted based on individual clinical response and tolerability. The recommended dosing regimens are detailed in Table 3.

Table 3: Recommended Dosing Regimens for Brivaracetam

Patient Population	Initial Dosage (Twice Daily)	Maintenance Dosage Range (Twice Daily)	Total Daily Dose Range
Adults (≥16 years)	50 mg	25 mg – 100 mg	50 – 200 mg/day
Pediatric Patients ≥50 kg	25 mg – 50 mg	25 mg – 100 mg	50 – 200 mg/day
Pediatric Patients 20 kg to <50 kg	0.5 mg/kg – 1 mg/kg	0.5 mg/kg – 2 mg/kg	1 – 4 mg/kg/day
Pediatric Patients 11 kg to <20 kg	0.5 mg/kg – 1.25 mg/kg	0.5 mg/kg – 2.5 mg/kg	1 – 5 mg/kg/day
Pediatric Patients <11 kg (≥1 month)	0.75 mg/kg – 1.5 mg/kg	0.75 mg/kg – 3 mg/kg	1.5 – 6 mg/kg/day
Dosages sourced from FDA prescribing information.35

B. Dose Adjustments in Specific Populations

Hepatic Impairment

Brivaracetam exposure is increased in patients with hepatic impairment, necessitating dose adjustments for all stages of liver disease. The reduced dosage recommendations are outlined in Table 4.

Table 4: Dose Adjustments for Hepatic Impairment

Patient Population	Recommended Starting Dosage (Twice Daily)	Recommended Maximum Maintenance Dosage (Twice Daily)	Total Maximum Daily Dose
Adults & Peds ≥50 kg	25 mg	75 mg	150 mg/day
Peds 20 kg to <50 kg	0.5 mg/kg	1.5 mg/kg	3 mg/kg/day
Peds 11 kg to <20 kg	0.5 mg/kg	2 mg/kg	4 mg/kg/day
Peds <11 kg	0.75 mg/kg	2.25 mg/kg	4.5 mg/kg/day
Dosages sourced from FDA prescribing information.35

Renal Impairment and Geriatric Considerations

No dose adjustment is required for patients with mild, moderate, or severe renal impairment.[59] However, its use is not recommended in patients with end-stage renal disease (ESRD) undergoing dialysis due to a lack of sufficient data.[54] For geriatric patients (≥65 years), while no specific dose adjustment is mandated, treatment should be initiated cautiously, generally starting at the lower end of the dosing range to account for the higher likelihood of comorbidities and decreased organ function.[56]

C. Clinically Significant Drug Interactions

Brivaracetam has a relatively low potential for drug-drug interactions compared to many older AEDs, primarily because its main metabolic pathway does not involve the CYP450 system. However, several clinically important interactions exist.

Interactions with Other Antiepileptic Drugs

• Carbamazepine: Brivaracetam is a reversible inhibitor of the enzyme epoxide hydrolase. This can lead to a significant increase (up to 198%) in the plasma concentration of carbamazepine-epoxide, the active metabolite of carbamazepine, which may increase the risk of toxicity. If tolerability issues arise, a reduction in the carbamazepine dose should be considered.[35]
• Phenytoin: Brivaracetam can increase plasma concentrations of phenytoin by approximately 20%. Therefore, it is recommended to monitor phenytoin levels when brivaracetam is initiated or discontinued.[35] Conversely, strong enzyme inducers like phenytoin can decrease brivaracetam exposure by about 21%.[64]
• Levetiracetam: Clinical studies have shown that co-administering brivaracetam with levetiracetam provides no additional therapeutic benefit.[35] This is likely due to competitive binding at the SV2A target. Therefore, these drugs should be used as alternatives to one another, not in combination.

Effects of Enzyme Inducers and Inhibitors

• Rifampin: Co-administration with rifampin, a potent enzyme inducer (particularly of CYP2C19), can decrease brivaracetam plasma concentrations by approximately 45%. It is recommended to double the brivaracetam dosage in patients taking concomitant rifampin.[35]
• Other Inducers: Other strong enzyme inducers like phenobarbital and St. John's wort can also increase the metabolism of brivaracetam and potentially reduce its efficacy.[64]
• CYP2C19 Inhibitors: Strong inhibitors of CYP2C19 (e.g., fluconazole) may increase brivaracetam exposure, and a dose reduction may be warranted.[62]

Interaction with CNS Depressants, including Alcohol

Brivaracetam can cause CNS depression (e.g., somnolence, dizziness). When combined with other CNS depressants, including alcohol, benzodiazepines, and opioids, these effects can be additive, leading to significant impairment.[12] A specific study demonstrated that brivaracetam potentiated the effects of alcohol on psychomotor function, attention, and memory.[1] Consequently, patients are strongly advised to avoid alcohol consumption while taking brivaracetam.[46]

Interaction with Oral Contraceptives

At the recommended maximum daily dose of 200 mg/day, brivaracetam is not expected to have a clinically significant effect on the efficacy of combined oral contraceptives.[69] However, studies using supratherapeutic doses (400 mg/day) showed a reduction in estrogen (27%) and progestin (23%) concentrations, suggesting a potential for interaction at very high doses, possibly through weak induction of CYP3A4.[34]

VII. Therapeutic Applications in Specific Clinical Contexts

A. Use in Patients with Intellectual Disabilities

Epilepsy is a frequent and often treatment-resistant comorbidity in individuals with intellectual disability (ID), presenting unique management challenges.[72] Real-world evidence indicates that brivaracetam is an effective and well-tolerated treatment option for this vulnerable population.[72] A UK-based study comparing patients with and without ID found that the efficacy of brivaracetam was comparable between the groups, with 12-month responder rates of 32.4% for patients with ID and 29.4% for those without.[74] Retention rates were also similar.

A particularly important clinical consideration in this population is the management of behavioral comorbidities. Levetiracetam is known to cause or exacerbate behavioral issues such as aggression and irritability. Multiple case reports and studies have demonstrated that switching patients with ID from levetiracetam to brivaracetam can lead to significant improvements in these behavioral adverse events, often while maintaining or improving seizure control.[72] This makes brivaracetam a valuable therapeutic alternative for patients with ID who are intolerant to levetiracetam.

B. Emerging Data on Use in Generalized Seizures

While brivaracetam is formally approved only for partial-onset seizures, its pharmacological profile and preclinical data suggest broad-spectrum anticonvulsant activity.[4] This has led to growing off-label use and investigation in various forms of generalized epilepsy. This practice is a logical extension of its mechanism; the SV2A target is ubiquitously expressed and relevant to multiple seizure types.

Clinical evidence, although still emerging and primarily from non-randomized studies, is promising. A narrative review of its use in genetic generalized epilepsies found high responder rates, ranging from 36% to 84%.[76] A case series of patients with genetic generalized epilepsy, including juvenile myoclonic epilepsy (JME), reported excellent control of generalized tonic-clonic seizures with brivaracetam as an add-on therapy.[77] Although further high-quality evidence from randomized controlled trials is needed, brivaracetam is increasingly considered a valid treatment alternative for patients with generalized seizures, particularly when other options have failed or are poorly tolerated.[78]

C. Investigational Use in Status Epilepticus

Status epilepticus (SE) is a neurological emergency requiring rapid and effective intervention. Brivaracetam is not currently approved for this indication, but its unique pharmacological properties make it an attractive candidate for the treatment of SE, especially in refractory cases.[33] The rationale for its use is compelling: it is available as an intravenous formulation that can be administered as a rapid bolus, it quickly penetrates the blood-brain barrier to engage its target within minutes, and it does not require slow titration.[33]

Several retrospective case series and systematic reviews have evaluated its off-label use in SE. These studies consistently report response rates for seizure termination in the range of 48-50%, often in patients who have failed to respond to first- and second-line treatments like benzodiazepines and other IV AEDs.[33] Some evidence suggests that higher loading doses, such as 2 mg/kg or more, are associated with a greater probability of a successful clinical response.[33] A consensus of experts has noted that intravenous brivaracetam is a valid alternative for SE after the failure of first-line therapy.[83] These findings support its potential role as a valuable tool in the acute management of this life-threatening condition.

VIII. Concluding Analysis and Recommendations

A. Synthesis of Brivaracetam's Clinical Profile

Brivaracetam represents a significant advancement in the treatment of epilepsy, born from a targeted effort to refine the properties of its predecessor, levetiracetam. Its clinical profile is defined by its highly selective, high-affinity binding to SV2A, coupled with a nearly ideal pharmacokinetic profile. This combination translates into a potent, rapidly acting, and predictable antiepileptic drug. Efficacy in controlling partial-onset seizures is well-established through a robust program of Phase III clinical trials, with sustained effectiveness demonstrated in long-term studies. Its safety profile is characterized primarily by manageable CNS side effects. The most critical aspect of its clinical identity is its relationship with levetiracetam; it offers a similar mechanism of action but with a potentially improved psychiatric tolerability profile, establishing a clear therapeutic niche.

Table 5: Comparative Profile of Brivaracetam vs. Levetiracetam

Feature	Brivaracetam	Levetiracetam	Source(s)
Primary Target	Synaptic Vesicle Protein 2A (SV2A)	Synaptic Vesicle Protein 2A (SV2A)	4
Relative SV2A Affinity	High (15-30x > Levetiracetam)	Moderate	4
Brain Penetration Speed	Fast (minutes)	Slower (up to 1 hour)	4
Approved Indications	Partial-onset seizures	Partial-onset, myoclonic, primary generalized tonic-clonic seizures	7
Titration Required?	No	Yes	4
Elimination Half-life (t1/2​)	~9 hours	6-8 hours	1
Primary Metabolism	Amidase hydrolysis (>90% metabolized)	Hydrolysis (~34% metabolized)	1
Common ADRs	Somnolence, dizziness, fatigue, nausea	Somnolence, asthenia, dizziness, infection	1
Reported Behavioral ADRs	Lower incidence (e.g., irritability, aggression)	Higher incidence; a common reason for discontinuation	15
Controlled Substance?	Yes (DEA Schedule V)	No	17
Generic Availability	No (as of 2023)	Yes	1

B. Key Therapeutic Advantages and Limitations

Advantages:

• Rapid Onset of Action: The ability to initiate treatment at a therapeutic dose without titration, combined with rapid brain penetration, allows for fast clinical effect.
• Improved Psychiatric Tolerability: Represents a key advantage over levetiracetam, making it a preferred option for patients with a history of or susceptibility to behavioral adverse events.
• Favorable Pharmacokinetics: Near-100% bioavailability, low protein binding, and primarily non-CYP metabolism result in predictable dosing and a lower risk of drug-drug interactions compared to many other AEDs.
• Formulation Flexibility: The availability of oral tablets, an oral solution, and an IV formulation provides for continuity of care across different clinical settings.

Limitations:

• Lack of Additive Benefit with Levetiracetam: It should be used as a replacement for, not an addition to, levetiracetam.
• CNS Side Effects: Somnolence and dizziness remain common and can be dose-limiting for some patients.
• Residual Psychiatric Risk: While the risk is lower, psychiatric adverse events can still occur and require diligent monitoring.
• Controlled Substance Status: Its classification as a Schedule V drug adds a layer of administrative requirement to its prescription.
• Cost and Generic Availability: As a branded medication, its cost is significantly higher than generic levetiracetam.

C. Recommendations for Clinical Practice and Patient Selection

Based on the comprehensive evidence, brivaracetam is a first-line option for both monotherapy and adjunctive therapy in patients with partial-onset seizures. Its use is particularly compelling in the following clinical scenarios:

1. Patients Intolerant to Levetiracetam: It is the logical next choice for patients who achieve seizure control with levetiracetam but experience intolerable behavioral or psychiatric side effects. An overnight switch is generally well-tolerated.
2. Patients Requiring Rapid Seizure Control: In newly diagnosed patients with frequent seizures, the ability to start at an effective dose without titration is a significant advantage.
3. Patients on Complex Polypharmacy: Its relatively "clean" pharmacokinetic profile and low potential for drug-drug interactions make it a suitable choice for patients taking multiple other medications.

Clinicians should remain aware of the growing body of evidence supporting its off-label use in generalized epilepsies and status epilepticus, applying clinical judgment when considering it in these contexts. Patient counseling should emphasize the potential for CNS side effects, the importance of avoiding alcohol, and the need to monitor for any changes in mood or behavior.

Works cited

1. Brivaracetam - Wikipedia, accessed August 4, 2025, https://en.wikipedia.org/wiki/Brivaracetam
2. Brivaracetam (Briviact): A Novel Adjunctive Therapy for Partial-Onset Seizures - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5265234/
3. Attachment: Product Information Brivaracetam - Therapeutic Goods ..., accessed August 4, 2025, https://www.tga.gov.au/sites/default/files/auspar-brivaracetam-170307-pi-01.pdf
4. Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy - PubMed Central, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11213745/
5. A review of the pharmacology and clinical efficacy of brivaracetam - PMC - PubMed Central, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5783144/
6. A review of the pharmacology and clinical efficacy of brivaracetam | CPAA, accessed August 4, 2025, https://www.dovepress.com/a-review-of-the-pharmacology-and-clinical-efficacy-of-brivaracetam-peer-reviewed-fulltext-article-CPAA
7. BRIVIACT® (brivaracetam) CV | Official Patient Website, accessed August 4, 2025, https://www.briviact.com/
8. Briviact (brivaracetam) FDA Approval History - Drugs.com, accessed August 4, 2025, https://www.drugs.com/history/briviact.html
9. Briviact (in Italy: Nubriveo) | European Medicines Agency (EMA), accessed August 4, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo
10. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4955277/
11. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies, accessed August 4, 2025, https://firstwordpharma.com/story/3997206
12. Brivaracetam: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 4, 2025, https://go.drugbank.com/drugs/DB05541
13. New indication for BRIVIACT® (brivaracetam): UCB's newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults - PR Newswire, accessed August 4, 2025, https://www.prnewswire.com/news-releases/new-indication-for-briviact-brivaracetam-ucbs-newest-antiepileptic-drug-approved-by-fda-as-monotherapy-treatment-of-partial-onset-seizures-in-adults-300520242.html
14. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies, accessed August 4, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000002864
15. Overnight switch from levetiracetam to brivaracetam. Safety and tolerability - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8640256/
16. Brivaracetam versus Levetiracetam for Epilepsy: A Review of Comparative Clinical Safety, accessed August 4, 2025, https://www.cda-amc.ca/brivaracetam-versus-levetiracetam-epilepsy-review-comparative-clinical-safety
17. Brivaracetam | C11H20N2O2 | CID 9837243 - PubChem, accessed August 4, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Brivaracetam
18. Brivaracetam: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed August 4, 2025, https://www.drugs.com/brivaracetam.html
19. Full article: Brivaracetam: A Newly Approved Medication for Epilepsy, accessed August 4, 2025, https://www.tandfonline.com/doi/full/10.2217/fnl-2015-0002
20. 205836Orig1s000 205837Orig1s000 205838Orig1s000 - accessdata.fda.gov, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205836Orig1s000_205837Orig1s000_205838Orig1s000RiskR.pdf
21. Cross Discipline Team Leader Review - FDA, accessed August 4, 2025, https://www.fda.gov/media/114521/download
22. FDA Approves Brivaracetam for Partial-Onset Seizures in Pediatric Epilepsy - NeurologyLive, accessed August 4, 2025, https://www.neurologylive.com/view/fda-approves-brivaracetam-iv-formulation-treat-partial-onset-seizures-pediatrics
23. BRIVIACT for Children | BRIVIACT® (brivaracetam) CV, accessed August 4, 2025, https://www.briviact.com/briviact-for-children
24. Brivaracetam | Exocytosis - Tocris Bioscience, accessed August 4, 2025, https://www.tocris.com/products/brivaracetam_7271
25. Brivaracetam | 357336-20-0 - ChemicalBook, accessed August 4, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB81508592.htm
26. Brivaracetam | Translocation, Exo/Endocytosis Products - R&D Systems, accessed August 4, 2025, https://www.rndsystems.com/products/brivaracetam_7271
27. Brivaracetam (UCB 34714, CAS Number: 357336-20-0) | Cayman Chemical, accessed August 4, 2025, https://www.caymanchem.com/product/34685/brivaracetam
28. CAS No : 357336-20-0 | Product Name : Brivaracetam - API - Pharmaffiliates, accessed August 4, 2025, https://www.pharmaffiliates.com/en/357336-20-0-brivaracetam-api-pa2948000.html
29. What is Brivaracetam used for? - Patsnap Synapse, accessed August 4, 2025, https://synapse.patsnap.com/article/what-is-brivaracetam-used-for
30. What is the mechanism of Brivaracetam? - Patsnap Synapse, accessed August 4, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-brivaracetam
31. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/26543353/
32. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/28012162/
33. Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma - Serval, accessed August 4, 2025, https://serval.unil.ch/resource/serval:BIB_B534E0801A68.P001/REF.pdf
34. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience - ResearchGate, accessed August 4, 2025, https://www.researchgate.net/publication/335695780_Levetiracetam_and_brivaracetam_a_review_of_evidence_from_clinical_trials_and_clinical_experience
35. Briviact (brivaracetam) Label - accessdata.fda.gov, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205836s009,205837s007,205838s006lbl.pdf
36. Brivaracetam in the treatment of epilepsy: a review of clinical trial data - PubMed Central, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6750854/
37. Brivaracetam Therapy and CYP2C19 Genotype - Medical Genetics Summaries - NCBI, accessed August 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK500036/
38. Brivaracetam Completed Phase 3 Trials for Epilepsy Treatment | DrugBank Online, accessed August 4, 2025, https://go.drugbank.com/drugs/DB05541/clinical_trials?conditions=DBCOND0017557&phase=3&purpose=treatment&status=completed
39. Efficacy and Safety of Adjunctive Brivaracetam for Partial-Onset (Focal) Seizures: Pooled Results from Three Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Phase III Studies (P2.022) - Neurology.org, accessed August 4, 2025, https://www.neurology.org/doi/10.1212/WNL.86.16_supplement.P2.022
40. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/38576178/
41. A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures | ClinicalTrials.gov, accessed August 4, 2025, https://clinicaltrials.gov/study/NCT00698581
42. BRIVA‐ONE study: 12‐month outcomes of brivaracetam monotherapy in clinical practice, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11633701/
43. Real-world safety evaluation of brivaracetam: insights from the US FDA Adverse Event Reporting System - ResearchGate, accessed August 4, 2025, https://www.researchgate.net/publication/388461865_Real-world_safety_evaluation_of_brivaracetam_insights_from_the_US_FDA_adverse_event_reporting_system
44. Brivaracetam Completed Phase 2 Trials for Epilepsy Treatment | DrugBank Online, accessed August 4, 2025, https://go.drugbank.com/drugs/DB05541/clinical_trials?conditions=DBCOND0017557&phase=2&purpose=treatment&status=completed
45. Brivaracetam-Induced Behavioral Changes - Thieme Connect, accessed August 4, 2025, https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0044-1779696.pdf
46. Briviact® (brivaracetam) for Epilepsy - Poison Control, accessed August 4, 2025, https://www.poison.org/articles/brivaracetam-for-epilepsy-223
47. Brivaracetam - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose | Drug Index | Pediatric Oncall, accessed August 4, 2025, https://www.pediatriconcall.com/drugs/brivaracetam/104
48. Brivaracetam Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 4, 2025, https://www.drugs.com/sfx/brivaracetam-side-effects.html
49. Brivaracetam: MedlinePlus Drug Information, accessed August 4, 2025, https://medlineplus.gov/druginfo/meds/a616027.html
50. Briviact: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed August 4, 2025, https://www.drugs.com/briviact.html
51. Important Safety Information | HCP - BRIVIACT® (brivaracetam) CV, accessed August 4, 2025, https://www.briviacthcp.com/important-safety-information
52. Brivaracetam (Briviact) - Epilepsy Medication, accessed August 4, 2025, https://www.cureepilepsy.org/understanding-epilepsy/treatments/epilepsy-medications/brivaracetam/
53. About Epilepsy Diagnosis | BRIVIACT® (brivaracetam) CV, accessed August 4, 2025, https://www.briviact.com/epilepsy-diagnosis
54. Brivaracetam (oral route) - Side effects & dosage - Mayo Clinic, accessed August 4, 2025, https://www.mayoclinic.org/drugs-supplements/brivaracetam-oral-route/description/drg-20311305
55. Safety & Side Effects - BRIVIACT.com, accessed August 4, 2025, https://www.briviact.com/side-effects
56. Briviact (brivaracetam) dosing, indications, interactions, adverse effects, and more, accessed August 4, 2025, https://reference.medscape.com/drug/briviact-brivaracetam-1000083
57. MEDICATION GUIDE BRIVIACT® (briv ee akt) CV (brivaracetam) tablets, oral solution, and injection for intravenous use What is th, accessed August 4, 2025, https://www.ucb-usa.com/briviact-medication-guide.pdf
58. Brivaracetam Basic Seizure Medication - Epilepsy Foundation, accessed August 4, 2025, https://www.epilepsy.com/tools-resources/seizure-medication-list/brivaracetam
59. Brivaracetam Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 4, 2025, https://www.drugs.com/dosage/brivaracetam.html
60. Dosing & Administration | BRIVIACT® (brivaracetam) CV, accessed August 4, 2025, https://www.briviacthcp.com/dosing
61. Reference ID: 4260979 - accessdata.fda.gov, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205836s005,205837s004,205838s003lbl.pdf
62. Specialist Initiated Drugs Prescribing Information Sheet February 2018, accessed August 4, 2025, https://www.eastkentformulary.nhs.uk/media/1248/brivaracetam-prescribing-guidelines-ekpg-recommendation-february-2018.pdf
63. Brivaracetam (Briviact), New Antiseizure Medication. All You Need to Know - YouTube, accessed August 4, 2025, https://m.youtube.com/watch?v=Y3QukH8Wgac&pp=ygUJI3Z5bWFkYTUw
64. Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/27146213/
65. What is the comparison between Brivaracetam (Brivacetam) and Levetiracetam (Keppra)?, accessed August 4, 2025, https://www.droracle.ai/articles/19936/brivacetam-vs-levetiracetam-
66. Briviact and Interactions: Other Drugs, Supplements, and More - Healthline, accessed August 4, 2025, https://www.healthline.com/health/drugs/briviact-interactions
67. Briviact, INN-brivaracetam - EMA, accessed August 4, 2025, https://www.ema.europa.eu/en/documents/product-information/briviact-epar-product-information_en.pdf
68. Pharmacological interactions between brivaracetam and ethanol in healthy males - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/27649776/
69. Epilepsy & Birth Control, accessed August 4, 2025, https://epilepsypregnancy.com/pregnancy-journey-topics/epilepsy-and-birth-control/
70. Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/24512385/
71. Briviact and etonogestrel Interactions - Drugs.com, accessed August 4, 2025, https://www.drugs.com/drug-interactions/briviact-with-etonogestrel-3728-17935-1056-0.html?professional=1
72. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy | Request PDF - ResearchGate, accessed August 4, 2025, https://www.researchgate.net/publication/339839045_Efficacy_and_tolerability_of_brivaracetam_in_patients_with_intellectual_disability_and_epilepsy
73. Case reports of improvement in behaviour following switching of patients with intellectual disability and epilepsy from levetiracetam to brivaracetam | Emerald Insight, accessed August 4, 2025, https://www.emerald.com/insight/content/doi/10.1108/AMHID-11-2019-0039/full/html
74. Consistent Treatment Effect Seen With Brivaracetam Across Patients With Intellectual Disability - NeurologyLive, accessed August 4, 2025, https://www.neurologylive.com/view/consistent-treatment-effect-brivaracetam-across-patients-intellectual-disability
75. New anti-seizure medication for elderly epilepsy patients - a critical narrative review, accessed August 4, 2025, https://www.researchgate.net/publication/346458059_New_anti-seizure_medication_for_elderly_epilepsy_patients_-_a_critical_narrative_review
76. Narrative review of brivaracetam for genetic generalized epilepsies - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/36332461/
77. clinical experience with brivaracetam in patients with genetic generalized epilepsy: a case series, accessed August 4, 2025, https://aesnet.org/abstractslisting/clinical-experience-with-brivaracetam-in-patients-with-genetic-generalized-epilepsy-a-case-series
78. Brivaracetam (Briviact) For Epilepsy | Dr. Omar Danoun, accessed August 4, 2025, https://dromardanoun.com/understand-epilepsy/antiseizure-medications/brivaracetam-briviact-for-epilepsy
79. Intravenous brivaracetam in status epilepticus: A retrospective single-center study, accessed August 4, 2025, https://firstwordpharma.com/story/4644713
80. Intravenous Brivaracetam in the Management of Acute Seizures in the Hospital Setting: A Scoping Review - Carolina Digital Repository, accessed August 4, 2025, https://cdr.lib.unc.edu/downloads/2n49tc22g
81. Efficacy and Tolerability of Intravenous Brivaracetam (Briviact®) for Status Epilepticus: A Systematic Review - CURE Epilepsy, accessed August 4, 2025, https://www.cureepilepsy.org/news/efficacy-and-tolerability-of-intravenous-brivaracetam-briviact-for-status-epilepticus-a-systematic-review/
82. Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/30530123/
83. Brivaracetam use in clinical practice: a Delphi consensus on its role as, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11306259/
84. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience - PMC - PubMed Central, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6734620/
85. Briviact vs. Keppra: How These Anti-Seizure Medications Differ - GoodRx, accessed August 4, 2025, https://www.goodrx.com/classes/anti-epileptics/briviact-vs-keppra
86. Keppra vs. Briviact for Epilepsy: Important Differences and Potential Risks. - GoodRx, accessed August 4, 2025, https://www.goodrx.com/compare/keppra-vs-briviact